



BSAC OPAT NATIONAL CONFERENCE 2013





UK Outpatient Parenteral Antimicrobial Therapy Initiative 2013 National Conference

The ICC Birmingham • 6th June 2013 • 09.00-16.30

Agenda				
09.00	Registration & Coffee			
	SESSION ONE: UK Overview, Standards & Outcomes			
09.30	Welcome & Overview Mark Gilchrist, Consultant Pharmacist, Imperial College Healthcare NHS Trust Dr Andrew Seaton, Consultant Physician, Gartnavel General Hospital, Glasgow			
09.35	The UK OPAT Initiative – then, now & in the future, overview of 2013 Audit Dr Andrew Seaton, Consultant Physician, Gartnavel General Hospital, Glasgow			
09.55	OPAT & Paediatric OPAT Standards and Practical Implications for the Hospital and Community Dr Sanjay Patel, Consultant Paediatrician, Southampton University Hospitals NHS Foundation Trust Dr Ann Chapman, Consultant in Infectious Diseases, Royal Hallamshire Hospital, Sheffield			
10.25	Recording OPAT treatment episodes and outcomes – review of the UK Patient Management System and initial data from the UK Outcomes Registry Mark Gilchrist, Consultant Pharmacist, Imperial College Healthcare NHS Trust			
10.45	Coding - the route to establishing an OPAT tariff Debbie Cumming, Pharmacist, NHS Isle of Wight			
11.05	Panel Discussion			
11.15	Coffee, Posters & Networking			

SESSION TWO: Concurrent Sessions

Chaired by	Case Development and Commissioning Or Graeme Jones, Consultant Microbiologist, Southampton Hospitals NHS Foundation Trust	Antimicrobial Agents and OPAT Chaired by Mark Gilchrist, Consultant Pharmacist, Imperial College Healthcare NHS Trust
11.50	Funding acquisition and business case development Dr Amandip Sahota, ST7 & Dr Susan Alleyne, Consultant Microbiolologist, University Hospitals of Leicester NHS Foundation Trust	Key considerations – choice of antimicrobial agents and managing the IV to oral switch Dr Andrew Seaton, Consultant Physician, Gartnavel General Hospital, Glasgow
12.05	Funding acquisition and business case development: A Scottish perspective Dr Claire Mackintosh, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh	
12.20	Commissioning OPAT services – balancing the elements Sharon Rourke, Senior Commissioning Manager, Acute and Service Redesign, NHS Blackpool Clinical Commissioning Group	Device choices for OPAT – stability data and patient safety Tim Hills, Antimicrobial Pharmacist, University Hospitals of Nottingham NHS Trust
12.35	Q&A	Q&A

12.45	Lunch, Posters & Practical Demonstrations				
13.45	Intravenous Antibiotics in Homecare – The Bupa Experience Stephen Cook, Director of Pharmacy, Bupa Home Healthcare				
	SESSION THREE: OPAT Experiences Chaired by Dr Andrew Seaton, Consultant Physician, Gartnavel General Hospital, Glasgow				
14.00	The district general hospital experience Dr Sajjad Mirza, Consultant Microbiologist, Royal Blackburn Hospital				
14.20	OPAT in the teaching hospital / tertiary centre Dr Ann Chapman, Consultant in Infectious Diseases, Royal Hallamshire Hospital, Sheffield				
14.40	OPAT community led service Sue O'Hanlon, Lead Nurse IV Therapy, Bridgewater Community Healthcare NHS Trust				
15.00	Panel Discussion				
15.10	Coffee & Networking				
	SESSION FOUR: NHS & Privately Provided OPAT Services Chaired by Dr Ann Chapman, Consultant in Infectious Diseases, Royal Hallamshire Hospital, Sheffield				
15.30	Horses for Courses - one model does not fit all!				
	A successful NHS provided service Sister Kate Owen, District Nurse, Dudley Group NHS Foundation Trust				
	Successful fulfilment of an OPAT service through a private provider Dr Susan Clarke, Clinical Lead for National OPAT Programme Ireland, St James' Hospital, Dublin				
16.20	Providing the best outcomes for patients - closing remarks Dr Frances Sanderson, Consultant in Infectious Diseases, Imperial College Healthcare NHS Trust				
16.30	Close				







SESSION ONE: UK Overview, Standards & Outcomes

Chaired by Mark Gilchrist & Dr Andrew Seaton









The UK OPAT Initiative-Then, Now & in the Future, Overview of 2013 Audit

Dr Andrew Seaton





The UK OPAT Initiative – then, now & in the future



R. Andrew Seaton

NHS Greater Glasgow and Clyde, Scotland, UK





OPAT Evidence, Experience and Consensus

- OPAT, CoPAT since early 80s in USA
 - North American practice guidelines published in 1998 and 2004
 - OPAT registry until c2002
- Hospital at the home in Australia (1990s-)
- O(H)PAT, NIPIV in Italy, Netherlands, Austria developing 1990s-

OPAT Evidence

- Disease–specific guidance (Endocarditis)
- 2 RCTs of OPAT: 1999 (n=100, variety) and 2004 (n=200, SSTI).
 - Mainly Cefazolin BD
- Hospital care at home systematic review (total 1327 patients) 2009
- RCTs of new antimicrobials includes OPAT Rx pts

von Reyn, Clin Infect Dis 2001; 32: 203 Corwin et al BMJ doi 10.1136/bmj.38309.447975.EB; Board et al *Aust N Z J Public Health 2000; 24:305* Shepperd et al CMAJ 2009; 180: 175

History of OPAT care in the UK

- Ad hoc development since mid-late 1990s
- Traditionally ID led
 - Oxford: Community based nursing team
 - Dundee: Hospital team with strong community nursing links
- Approx 32 centres in 1999
- UK consensus statement 1998
- European consensus 2000
- Patient Group Directions 2005 (UK, SSTI)

Nathwani and Conlon Clin Micro Infect 1998; Nathwani Clin Micro Infect Dis 2000 Seaton et al JAC 2005

Barriers to OPAT in the UK (1999)

Survey of UK Infection Specialists (n=157)*

Perceived barrier to OPAT	Proportion of respondents, %
Funding issues	35
Difficult to co-ordinate/oversee care	30
Fragmented distribution of patients	27
Training issues	17
Lack of guidelines/experience	13
Time constraints	11
Safety (line care or drug administration)	10
Geographical constraints	5

^{*} Estimate of 32 OPAT services in UK

BSAC OPAT Initiative 2009



Objectives:

- Publication of peer reviewed standards for the delivery of OPAT services
- Business case models to assist HCPs develop local OPAT services
- Measure the impact of the project (clinical effectiveness, economic impact, patient experience)
- UK-wide educational workshops to inform, instruct and support those wishing to implement OPAT services in their locality
- Development of web-based educational resources to support those with, or wishing to establish, OPAT





BSAC OPAT Projects 2009 -

- UK Stakeholder Meeting 2009: Chair Dilip Nathwani
- Working parties established
 - OPAT Good Practice recommendations:BSAC/BIA
 - OPAT Business Case toolkit
 - OPAT Patient Management System & Registry
- E-OPAT
- UK Workshops

UK OPAT Status 1999 vs 2011

		1999		2011		
Infection sp. Contacted		345		296		
Response to survey		46%		66%		
Existing OPAT service	Existing OPAT service		32 (21%)		107 (64%)	
OPAT service + like to expand		-		85 (86%)		
No OPAT but like to develop		125 (61%)		48 (81%)		
Main development barriers:						
		Funding	35%	Clinician	24%	
		Leadership	34%	Nurse	23%	
		Coordination	37%	Bus. case	20%	





European Summit on OPAT 2011







Website <u>www.e-opat.com</u> launched 2011

Home Resources 2012 Meetings Patient Management System Business Case Toolkit Outcomes Registry Partners









Congratulations Dundee - Patient Management System installed

Congratulations to Dundee who are trailblazers for the new OPAT Patient Management System. The OPAT team is looking forward to using the PMS, commonly known as the OPAT database, and being the first contributors to the UK National OPAT Register. The Patient Management System is now available for installation across the United Kingdom and Ireland. [...]



Meetings

Who Should Attend?

Register



Tools

The Business Case Toolkit

OPAT Patient Management System

Outcomes Registry





Good Practice recommendations available to download from website 2012

Journal of Antimicrobial Chemotherapy Advance Access published January 31, 2012

J Antimicrob Chemother doi:10.1093/jac/dks003

Journal of Antimicrobial Chemotherapy

Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement

Ann L. N. Chapman^{1*}, R. Andrew Seaton², Mike A. Cooper³, Sara Hedderwick⁴, Vicky Goodall¹, Corienne Reed⁵, Frances Sanderson⁶ and Dilip Nathwani⁷ on behalf of the BSAC/BIA OPAT Project Good Practice Recommendations Working Group†

¹Department of Infection and Tropical Medicine, Royal Hallamshire Hospital, Sheffield S10 2JF, UK; ²Brownlee Centre, Gartnavel General Hospital, Glasgow G12 0YN, UK; ³Department of Microbiology, New Cross Hospital, Wolverhampton WV10 0QP, UK; ⁴Royal Victoria Hospital, Belfast BT12 6BA, UK; ⁵Salford Royal Foundation Trust, Salford M6 8HD, UK; ⁶Clinical Infectious Diseases, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK; ⁷Ninewells Hospital & Medical School, Dundee DD1 9SY, UK

Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement

- 1. OPAT team and service structure
- 2. Patient selection
- 3. Antimicrobial management and drug delivery
- 4. Monitoring of the patient during OPAT
- 5. Outcome monitoring and clinical governance


Journal of Antimicrobial Chemotherapy Advance Access published January 31, 2012

Journal of Antimicrobial Chemotherapy






OPAT software tools launched in 2012







Patient Management System




The British Society for Antimicrobial Chemotherapy (BSAC) © 2012 Registered Charity 1093118. Registered as a company limited by guarantee in England & Wales No: 4443910.

Except as may be provided in a separate written license or other agreement this system is provided to you on an 'as is' and 'as available' basis. Neither BSAC nor its partners will be liable for any punitive, incidental, special, consequential or other losses or damages arising out of or related to use of this system whether as a result of errors, omissions, loss of data, defects, interruptions or delays in operation or transmission, or any other cause.





OPAT Registry




Powered by Pharma Mix - Help - Disclaimer

The British Society for Antimicrobial Chemotherapy (BSAC) © 2012 Registered Charity 1093118. Registered as a company limited by guarantee in England & Wates No. 4443910.

BSAC OPAT Workshops

- 8 Events, UK wide
- Feedback from >200 attendees
 - 98.1% presentations appropriate
 - 97.6% meeting content adequate for educational needs
 - 97.5% excellent/ good workshop

Attendees



BSAC OPAT Workshops: Feedback...

- More on antimicrobial regimens including oral Rx and PK/PD
- More case based discussions
- More "practical tips"
- More discussion on antimicrobial choices. It appeared that ceftriaxone and teicoplanin were the mainstay of antimicrobial treatment options. This can have problems such as CDI and VRE/GRE respectively. Plus, they wouldn't be common treatment choices in (my) hospital setting, begging the question 'are patients getting better treatment by staying in hospital?'

BSAC OPAT Standing Committee 2013





Workstreams

- Patient Management System, Audit and National Outcomes Registry
- Community Led OPAT Services
- Economics and Coding
- Paediatric OPAT (P-OPAT)
- Drug Stability and Testing
- Oral therapies, Antimicrobial Stewardship and OPAT





2013 Standing Committee

Dr Matthew Dryden, Hampshire

BSAC General Secretary | Chair of the IV to Oral Switch in the OPAT Setting Work stream

Dr Mike Cooper, Consultant Microbiologist, Wolverhampton

BSAC Meetings Secretary

Dr Andrew Seaton, Consultant Physician, Glasgow

Co-Chair of the Standing Committee

Dr Mark Gilchrist, Consultant Infectious Diseases Pharmacist, London

Co-Chair of the Standing Committee |Chair, Patient Management System Work stream | Member Audit and National Outcomes Registry Work stream | Member, Drug Stability and Testing Work stream

Dr Graeme Jones, Consultant Microbiologist, Southampton

Co-Chair, Economics and Coding Work stream

Debbie Cummings, Pharmacist, Isle of Wight

Co-Chair, Economics and Coding Work stream

Tim Hills, Antimicrobial Pharmacist, Nottingham

Co-Chair, Drug Stability and Testing Work stream

Dr Susan Snape, Consultant in Infectious Diseases, Nottingham

Co-Chair, Drug Stability and Testing Work stream

Dr Frances Sanderson, Consultant in Infectious Diseases, London

Chair, Community Led OPAT Services Work stream

Dr Sanjay Patel, Consultant Paediatrician, Southampton

Chair, Paediatric OPAT (P-OPAT) Work stream | Member, Patient Management System, Audit and National Outcomes Registry Work stream

Dr Ann Chapman, Consultant in Infectious Diseases, Sheffield

Member, Community Led OPAT Services Work stream

Dr Paul Jhass, Advanced Pharmacist, Kent

Member, Community Led OPAT Services Work stream


Sue O'Hanlon, Lead Nurse IV Therapy, Bridgewater

Nursing Lead | Member, Community Led OPAT Services Work stream

2013 Survey of 193 Trusts/HBs

- 119 (63%) response
- 68% have service
- 82% Hospital based
- 85% would like to extend the service
- 57% Nurse resource main barrier to development


2013: OPAT Models




2013 Survey: No OPAT service

- 87% would like an OPAT service
- 41%: Cost most important reason for not having a service
- 60%: Nurse/ clinician availability main barrier to service provision

Status of OPAT: Proposed Model



Status of OPAT Development








OPAT in the UK: The Future?

- Peer support of further OPAT development
- Funding and reimbursement: Tackle at national level
- UK roll out of OPAT Patient Management System
- UK-wide centre upload of data to OPAT Registry
- Release of paediatric software tools (POPAT)


Managing Length of Stay





Acknowledgement: Gautam Ray

2011 Survey: Which patients would you like to extend to?



Challenges of Emerging UK models of OPAT

Leadership	Complex infection Mx expertise	Inpatient resource	Facility to avoid admission	Pan hospital reach	"Ubiquity"
ID specialist			\	**	
Microbiology	**				
Acute/ Emergency medicine					
Primary care					

OPAT trends over 10 yrs in NHS GGC

	Trend over time	
Referral from non-local hospital	$1 \qquad X^2_{\text{trend}} = 72.92$	p < 0.0001
Referral from secondary care	$1 \qquad X^2_{\text{trend}} = 26.07$	p < 0.0001
Co-morbidity	$1 \qquad X^2_{\text{trend}} = 24.07$	p < 0.0001
Non-SSTI infection	$1 \qquad X^2_{\text{trend}} = 97.14$	p < 0.0001
MRSA infections (as % of <i>S. aureus</i>)	$X^{2}_{trend} = 6.682$	p = 0.0097
G-ve infections (% of +ve cultures)	$X^{2}_{trend} = 10.491$	p = 0.0012
Self / carer antibiotic admin	$1 \qquad X^2_{\text{trend}} = 48.49$	p < 0.0001

Barr et al, IJAA 2012





OPAT in the UK: Challenges?

- Changing hospital population
- Antimicrobial Stewardship
 - Infection specialist leadership
 - IVOST and Duration of Therapy
 - Restrictions on IV agents (stability / frequency of administration))
- Engagement with "OPAT" within other models of ambulatory care
- Funding and OPAT tariffs

Summary and Conclusions

- Interest and practice of OPAT growing in UK
- Different models of care developing with different focus
- Key developments via the BSAC Initiative
- Resource/ personnel, "business case" development main barriers to development and expansion
- Funding and reimbursement is a challenge

Acknowledgements

Tracey Guise, Esme Caruthers (BSAC), Terri Martin and Debbie Lancaster (Pharma Mix), Mark Gilchrist and BSAC standing committee members Past OPAT initiative chair Dilip Nathwani





